论文部分内容阅读
血脂异常是心血管疾病主要危险因素之一,调脂可减少血管硬化及相关并发症的发生、发展。前蛋白转化酶枯草溶菌素9(PCSK9)与血脂代谢密切相关,它通过在溶酶体内降解低密度脂蛋白受体提升血胆固醇水平。目前对PCSK9的研究已取得一定进展,PCSK9单克隆抗体可以通过抑制PCSK9的活性,使血液中的LDL-C水平降低。目前PCSK9单克隆抗体已经完成Ⅰ期、Ⅱ期临床研究,Ⅲ期临床研究正在进行中。本文中作者就目前PCSK9及单克隆抗体在脂代谢调节中作用作一综述,旨在对降脂单抗药物研发与临床应用作为参考。
Dyslipidemia is one of the major risk factors of cardiovascular diseases. Lipid-lowering can reduce the occurrence and development of vascular sclerosis and related complications. Pro-protein convertase subtilisin 9 (PCSK9) is closely linked to lipid metabolism, which enhances blood cholesterol levels by degrading low-density lipoprotein receptors in lysosomes. At present, the research on PCSK9 has made some progress. The PCSK9 monoclonal antibody can reduce the level of LDL-C in the blood by inhibiting the activity of PCSK9. Currently PCSK9 monoclonal antibody has completed Phase I, Phase II clinical studies, Phase III clinical studies are underway. In this paper, the authors reviewed the current role of PCSK9 and monoclonal antibodies in the regulation of lipid metabolism, aimed at the lipid-lowering monoclonal antibody development and clinical application as a reference.